Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma

Andrea Katharina Lindner; Martin Pichler; Martin Thurnher; Renate Pichler

doi:10.1016/j.eururo.2021.10.025

Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma

Eur Urol. 2022 Jan;81(1):1-2. doi: 10.1016/j.eururo.2021.10.025. Epub 2021 Nov 15.

Authors

Andrea Katharina Lindner¹, Martin Pichler², Martin Thurnher³, Renate Pichler⁴

Affiliations

¹ Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
² Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Urology, Medical University of Innsbruck, Innsbruck, Austria; Immunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: martin.thunher@i-med.ac.at.
⁴ Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: renate.pichler@i-med.ac.at.

PMID: 34794854
DOI: 10.1016/j.eururo.2021.10.025

Abstract

c-Met inhibition has direct antitumor effects on proliferation, angiogenesis, and metastasis, and indirect antitumor effects via prevention of the induction of immunosuppressive mechanisms (PD-L1, TGFβ, IDO1). c-Met inhibition is key to overcome resistance to immune checkpoint inhibition and to maximize the efficacy of immunotherapy.

Keywords: Cabozantinib; Immunotherapy; RCC; Resistance; c-MET.

Publication types

Editorial

MeSH terms

Carcinoma, Renal Cell* / pathology
Female
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Kidney Neoplasms* / pathology
Male
Neovascularization, Pathologic

Substances

Immune Checkpoint Inhibitors